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ABSTRACT 1 
Background: The aim of this study was to identify a new plasma biomarker for use in 2 
early detection of colorectal cancer.  3 
Methods: Using the combination of hollow-fiber-membrane (HFM)-based 4 
low-molecular weight protein enrichment and 2-Dimensional Image Converted Analysis 5 
of Liquid chromatography and mass spectrometry (2DICAL), we compared the plasma 6 
proteome of 22 colorectal cancer patients to those of 21 healthy controls. An identified 7 
biomarker candidate was then validated in two larger cohorts [Validation-1 (n = 210) 8 
and Validation-2 (n = 113)] using a high-density reverse-phase protein microarray. 9 
Results: From a total of 53,009 mass peaks, we identified 103 with an area-under-curve 10 
(AUC) value of 0.80 or higher that could distinguish cancer patients from healthy 11 
controls. A peak that increased in colorectal cancer patients, with an AUC of 0.81 and 12 
P-value of 0.0004 (Mann-Whitney U-test), was identified as a product of the PLIN2 13 
gene [also known as perilipin-2, adipose differentiation-related protein (ADRP), or 14 
adipophilin]. An increase in plasma adipophilin was consistently observed in colorectal 15 
cancer patients, including those with stage I or stage II disease (P < 0.0001, Welch’s 16 
t-test). Immunohistochemical analysis revealed that adipophilin is expressed primarily 17 
in the basal sides of colorectal cancer cells forming polarized tubular structures, and that 18 
it is absent from adjacent normal intestinal mucosae.  19 
Conclusions: Adipophilin is a plasma biomarker potentially useful for the detection of 20 
early-stage colorectal cancer. 21 
Impact: The combination of HFM and 2DICAL enables the comprehensive analysis of 22 
plasma proteins and is ideal for use in all biomarker discovery studies. 23 
24 
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Introduction 1 
Colorectal cancer is the second leading cause of cancer deaths in Western countries (1), 2 
and is the third leading cause of cancer deaths in Japan, where there were more than 3 
43,000 estimated colorectal cancer deaths in 2008 (2). Treatment of colorectal cancer 4 
without metastasis is relatively uncomplicated, and a favorable prognosis can be 5 
expected for these patients (3, 4). However, the 5-year survival rate of patients with 6 
metastatic colorectal cancer is estimated to be less than 5% (5), underscoring the 7 
importance of early detection. The modality used most commonly for colorectal cancer 8 
mass screening is fecal occult blood (FOB) test. Three large randomized trials 9 
demonstrated that inclusion of FOB in colorectal cancer screening significantly reduces 10 
the rates of colorectal cancer mortality (6-8). However, FOB has a relatively high 11 
false-positive rate (9, 10), and as a result, a large number of healthy individuals receive 12 
radiological or endoscopic re-examination after the FOB test, placing excessive physical 13 
and physiological burdens on examiners and examinees, as well as imposing an undue 14 
financial burden upon society. The only approved screening alternative to FOB for the 15 
diagnosis of colorectal cancer is testing for the tumor marker carcinoembryonic antigen 16 
(CEA). Unfortunately, CEA is not useful as a marker for the early detection of 17 
colorectal cancer (11). Therefore, it is necessary to identify a new biomarker to 18 
supplement these current diagnostic modalities. 19 
Alterations in the protein content of clinical samples reflect the dynamic 20 
biological changes of patients more directly than changes in mRNA levels (12). 21 
Plasma/serum proteins are thus valuable resources for the discovery of biomarkers with 22 
direct clinical application. We previously developed a quantitative proteomics platform, 23 
called 2DICAL (13). This technology is especially advantageous in clinical studies in 24 
which a large number of patient samples must be compared. We were able to identify a 25 
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number of plasma/serum biomarkers with high potential for clinical application using 1 
2DICAL (14-18). However, the direct analysis of plasma/serum proteins using 2DICAL 2 
remains technically challenging. Proteins secreted by cancer cells are considerably 3 
diluted in the blood circulation and present only in a low concentration (19, 20). The 4 
concentration of serum/plasma proteins ranges over more than 10 orders of magnitude, 5 
and thus the efficient removal of abundant plasma/serum proteins is essential for the 6 
detection of low-abundance cancer-related biomarker proteins (21). 7 
In this study we applied a high-performance hollow-fiber membrane (HFM) 8 
technology to the enrichment of low-molecular weight (LMW) proteins (17, 22) and 9 
searched for new plasma biomarkers that might be applicable to the early diagnosis of 10 
colorectal cancer. The LMW plasma protein fraction is made up of various functional 11 
proteins, such as cytokines, chemokines, and peptides, and is considered to be a rich 12 
unexplored archive of biologic information (20). The HFM-based technique (HFMT) 13 
utilizes a fully automated system that can separate and concentrate low-abundance 14 
plasma proteins from relatively high-molecular weight abundant proteins such as 15 
albumin, immunoglobulin, transferrin, and apoliporptroteins with high efficiency and 16 
reproducibility (22). Here, we report the identification of adipophilin, an 17 
adipose-differentiation-related protein, as a novel tumor marker for colorectal cancer 18 
through a comprehensive analysis of the LWM plasma proteome of colorectal cancer 19 
patients using HFM and 2DICAL technologies. 20 
 21 
 22 
Patients and Methods 23 
Plasma samples 24 
Plasma samples were collected prospectively from 366 individuals and then split 25 
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randomly into three cohorts (Training, Validation-1 [V1], and Validation-2 [V2]) (Table 1 
1). The cohorts were essentially hospital-based, and consisted of healthy volunteers and 2 
newcomers (primarily to gastrointestinal services) between August 2006 and October 3 
2008 at the following seven hospitals in Japan: National Cancer Center Hospital 4 
(NCCH; Tokyo), Osaka National Hospital (ONH; Osaka), Jichi Medical School 5 
Hospital (JMS; Shimotsuke), Osaka Medical Center for Cancer and Cardiovascular 6 
Diseases (Osaka), Tokyo Medical University Hospital (TMUH; Tokyo), Osaka Medical 7 
College Hospital (OMC; Osaka), and Fukuoka University Hospital (Fukuoka). This 8 
multi-institutional collaborative study group was organized by the “Third-Term 9 
Comprehensive Control Research for Cancer” conducted by the Ministry of Health, 10 
Labour and Welfare of Japan and joined the International Cancer Biomarker Consortium 11 
(23). Written informed consent was obtained from every subject. 12 
All patients diagnosed as having cancer had histological or cytological proof of 13 
colorectal adenocarcinoma. Demographic and laboratory data for the cases are 14 
summarized in Table 1. The staging of cancer was defined according to TNM 15 
classification by the International Union against Cancer (UICC). The Training cohort 16 
comprised 43 cases, including untreated colorectal cancer patients from TMUH (n = 8), 17 
JMS (n = 9), and ONH (n = 5), and healthy controls from NCCH (n = 2), TMUH (n = 9), 18 
OMC (n = 6), and ONH (n = 4). The V1 and V2 cohorts comprised 210 and 113 cases, 19 
respectively, from the seven hospitals as described above. The V1 cohort included 101 20 
patients with colorectal cancer and 109 healthy controls. The V2 cohort comprised 26 21 
patients with colorectal cancer and 87 healthy controls. 22 
For all the samples used in this study, the same protocol was used for blood 23 
collection, storage, and freeze/thawing to ensure absence of any pre-analytical bias 24 
caused by differences in sample handling. Blood was collected in a tube with 25 
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ethylenediaminetetraacetic acid (EDTA) at the time of diagnosis. Plasma was separated 1 
by centrifugation and frozen at -80°C until analysis. Macroscopically hemolyzed 2 
samples were excluded from the present analysis. The protocol of this study was 3 
reviewed and approved by the institutional ethics committee board of each participating 4 
institute. 5 
 6 
Depletion of high-molecular weight plasma proteins 7 
The plasma samples of the Training cohort were filtered through a 0.22-μm-pore-size 8 
filter. Five hundred microliter of the sample was diluted by adding 3.5 mL 25mM 9 
ammonium bicarbonate buffer (pH 8.0). The total of 4 mL of the plasma dilution was 10 
injected into a HFMT machine (22). After one hour of fully automated operation, the 11 
solution containing LMW proteins was recovered and lyophilized. 12 
 13 
LC-MS 14 
The HFMT-treated samples were digested with sequencing-grade modified trypsin 15 
(Promega, Madison, WI) and analyzed in duplicate using a nano-flow high-performance 16 
liquid chromatography (HPLC) (NanoFrontier nLC, Hitachi High-technologies, Tokyo, 17 
Japan) connected to an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) 18 
mass spectrometer (Q-Tof Ultima, Waters, Milford, MC). 19 
 MS peaks were detected, normalized, and quantified using the in-house 20 
2DICAL software package, as described previously (13). A serial identification (ID) 21 
number was applied to each of the MS peaks detected (1 to 53009). The stability of 22 
LC-MS was monitored by calculating the correlation coefficient (CC) and coefficient of 23 
variance (CV) of every measurement. For all 53,009 peaks observed in the 43 duplicate 24 
runs, the mean CC (± SD) was as high as 0.951 (± 0.039) and the mean CV was as low 25 
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as 0.054 (± 0.011). 1 
 2 
Protein identification by tandem mass spectrometry (MS/MS) 3 
Peak lists were generated using the Mass Navigator software package (version 1.2) 4 
(Mitsui Knowledge Industry, Tokyo, Japan) and the peak lists were searched against the 5 
SwissProt database (downloaded on April 22, 2009) using the Mascot software package 6 
(version 2.2.1) (Matrix Science, London, UK). The search parameters used were as 7 
follows: the human protein database was selected; up to one missed cleavage was 8 
allowed; “none” was designated as the enzyme; mass tolerances for precursor and 9 
fragment ions were ± 0.6 Da and ± 0.2 Da, respectively; the score threshold was set to P 10 
< 0.05 based on the size of the database used in the search. If a peptide matched 11 
multiple proteins, the protein name with the highest Mascot score was selected. 12 
 13 
Immunoblot analysis 14 
Primary antibodies used were mouse monoclonal antibody against adipophilin 15 
(LifeSpan Biosciences, Seattle, WA) and mouse monoclonal antibody against human 16 
complement C3b-α (PROGEN, Heidelberg, Germany). Ten microliter of 1:50 diluted 17 
plasma sample and 0.3 μg of fully recombinant adipophilin (BioVendor, Modrice, Czech 18 
Republic) as positive control were separated by SDS-PAGE and electroblotted onto a 19 
polyvinylidene difluoride membrane. The membrane was then incubated with primary 20 
antibody followed by horseradish peroxidase-conjugated anti-mouse IgG as described 21 
previously (24, 25). Blots were developed using an enhanced chemiluminescence (ECL) 22 
detection system (GE Healthcare, Buckinghamshire, UK). 23 
 24 
Reverse-phase protein microarray 25 
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The plasma samples from the V1 and V2 cohorts were serially diluted 1:32, 1:64, 1:128, 1 
and 1:256 using a Biomek 2000 Laboratory Automation Robot (Beckman Coulter, 2 
Fullerton, CA), and randomly plotted onto ProteoChip® glass slides (Proteogen, Seoul, 3 
Korea) in quadruplicate in a 6144-spot/slide format using a Protein Microarrayer Robot 4 
(Kaken Geneqs, Matsudo, Japan). The spotted slides were incubated overnight with the 5 
same primary antibody as used in Western blotting. The slides were incubated with 6 
biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA) followed by 7 
streptavidin-horseradish peroxidase conjugate (GE Healthcare, Buckinghamshire, UK). 8 
Peroxidase activity was detected using the Tyramide Signal Amplification (TSA®) 9 
Cyanine 5 System (PerkinElmer, Waltham, MA). The slides were counterstained with 10 
Alexa Fluor® 546-labeled goat anti-human IgG (Invitrogen, Eugene, OR) (spotting 11 
control). 12 
The stained slides were scanned on a microarray scanner (InnoScan® 700AL, 13 
Innopsys, Carbonne, France). Fluorescence intensity, determined as mean values of 14 
quadruplicate samples, was determined using the Mapix® software (Innopsys, Carbonne, 15 
France). All intensity values were transformed into logarithmic variables. The 16 
reproducibility of our reverse-phase protein microarray assay was reported previously 17 
(18).  18 
 19 
Immunohistochemistry 20 
Twenty colorectal cancer cases were selected from the surgical pathology archive panel 21 
of the National Cancer Center Hospital, as described previously (24). Sections (4-μm 22 
thick) were cut from paraffin blocks of colorectal cancer tissues and mounted on 23 
silanized glass slides, and were subsequently stained by the avidin-biotin complex 24 
method. The primary antibody was the same as used in immunoblot analysis. 25 
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 1 
Statistical analysis 2 
The statistical significance of inter-group differences was assessed with the Wilcoxon 3 
test, Mann-Whitney U-test, Welch’s t-test, Kruskal-Wallis test, or Fisher’s exact test, as 4 
appropriate. The area under the curve (AUC) value of the receiver operating 5 
characteristics (ROC) analysis was calculated for each marker to evaluate its diagnostic 6 
significance using ROCKIT software (version 0.9.1; the Kurt Rossmann Laboratories, 7 
Chicago, IL). A composite index of two markers was generated using the result of 8 
multivariate logistic regression analysis, which also enabled the calculation of 9 
sensitivity, specificity, and ROC curves. Statistical analyses were performed using an 10 





Plasma biomarker discovery by quantitative MS  16 
To identify a diagnostic biomarker for patients with colorectal cancer including those 17 
with early-stage diseases, we compared the plasma proteomes of 22 colorectal cancer 18 
patients with those of 21 healthy controls (Training cohort) using 2DICAL (Table 1). 19 
Among a total of 53,009 independent MS peaks detected within the range 250-1,600 20 
m/z and within the time range 20-70 minutes, we found 103 peaks with a discriminatory 21 
AUC value of > 0.800. A representative 2-dimensional view of all the MS peaks, with 22 
the m/z displayed along the X-axis and the LC retention time (RT) along the Y-axis, is 23 
shown in Figure 1A. The 103 MS peaks which distinguished between colorectal cancer 24 
patients and healthy controls with AUC values of > 0.800 are highlighted in red. 25 
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Eleven MS/MS spectra acquired from those 103 peaks matched six proteins in 1 
the database with Mascot score > 40 (Supplementary Table S1). We focused attention on 2 
a MS peak (ID 83) derived from the amino acid sequence of ADFP gene product 3 
(Supplementary Fig. S1), because the expression level of adipophilin was previously 4 
reported to be upregulated in clear cell renal carcinoma, but no such upregulation has 5 
been described in colorectal cancer. The adipophilin-derived MS peak (ID 83, at 749 6 
m/z and 47.4 minutes) in representative patients from cancer and control groups is 7 
shown in Figure 1B. The distribution of the MS peak (ID 83) in patients with colorectal 8 
cancer (red) and healthy controls (blue) in the Training cohort (AUC = 0.814) is shown 9 
in Figure 1C. The differential expression and identification of adipophilin was 10 
confirmed by denaturing SDS-PAGE and immunoblotting analyses (Fig. 1D).  11 
 12 
Protein microarray validation 13 
To further validate the utility of using adipophilin for the diagnosis of colorectal cancer, 14 
the relative level of adipophilin in a total of 323 plasma samples was quantified using 15 
reverse-phase protein microarrays (Fig. 2). Quadruplicate spots for representative cases 16 
with high and low levels of adipophilin are shown in Figure 2. The power of plasma 17 
adipophilin level to discriminate colorectal cancer was validated in two larger 18 
independent Validation cohorts (V1: n = 210, V2: n = 113) that included early-stage 19 
colorectal cancer (Table 1). In the V1 cohort, the adopophilin level was significantly 20 
higher in patients with colorectal cancer than in healthy controls (Welch’s t-test P = 21 
5.49×10-10, Fig. 3A and Table 1), with an AUC value of 0.767 [95% confidential 22 
interval (CI): 0.699-0.825] (Fig. 3B). The colorectal cancer discriminatory power of 23 
adipophilin was also apparent in the V2 cohort (P = 0.00009, Fig. 3C and Table 1), with 24 
an AUC value of 0.742 [95% CI: 0.625-0.836] (Fig. 3B). 25 
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 There was no difference in the plasma level of adipophilin among different 1 
disease stages (Kruskal-Wallis test P = 0.280). Notably, however, the adipophilin level 2 
was significantly higher even in patients with stage I or II disease (localized early 3 
colorectal cancer without metastasis to lymph nodes) than in healthy controls, while the 4 
CEA level in early-stage patients did not significantly differ from that of healthy 5 
controls (Table 2).  6 
 7 
Adipophilin complements CEA 8 
The levels of adipophilin and CEA were not mutually correlated (Pearson’s r = 0.13 in 9 
the V1 cohort and 0.12 in the V2 cohort), and the AUC values of CEA in both cohorts 10 
(Fig. 3D) were comparable to that of a previous report (26). Combining adipophilin and 11 
CEA quantitation yielded a significant improvement in the ability to distinguish patients 12 
with colorectal cancer from healthy controls compared to quantitating CEA alone; the 13 
AUC improved to 0.849 [95% CI: 0.790-0.896] in the V1 cohort (P = 0.0008) and 0.787 14 
[0.673-0.874] in the V2 cohort (P = 0.022) (Fig. 3D), indicating that plasma adipophilin 15 
and CEA have complementary diagnostic utility.  16 
 Due to the low prevalence of colorectal cancer among an asymptomatic 17 
population, a high specificity is required for a screening biomarker. If we defined the 18 
upper limit of the normal range of the composite index (adipophilin plus CEA; Fig. 3D) 19 
to include 95% of healthy controls in each validation cohort, the sensitivity of the index 20 
was 54% [95% CI: 41-66%] in the V1 cohort and 31% [13-56%] in the V2 cohort. 21 
 22 
Adipophilin expression in colorectal cancer 23 
The expression and cellular distribution of adipophilin in colorectal cancer tissues were 24 
examined using an immunohistochemical assay of eight well-differentiated, ten 25 
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moderately-differentiated, and two poorly-differentiated adenocarcinomas. A total of 14 1 
of 20 cancer tissues from the well- and moderately-differentiated cases showed positive 2 
staining for adipophilin, but neither of the two poorly-differentiated samples was 3 
positive. In a majority of the well- and moderately-differentiated tumors, strong staining 4 
for adipophilin was observed in the cytoplasm or cell membrane of tumor glands facing 5 
the basement membrane (Fig. 4A and 4B). Adipophilin was not expressed in normal 6 
epithelial cells of the colorectal mucosa (Fig. 4C). The expression of adipophilin was 7 
clearly diminished in cancer cells invading in a scattered manner (Fig. 4D), which is 8 




In the present study, we first enriched the LMW plasma protein fraction using HFMT, 13 
then compared its contents between patients with colorectal cancer and healthy controls 14 
using 2DICAL (Fig. 1). The high efficacy of combining HFMT and 2DICAL for plasma 15 
biomarker discovery was demonstrated for the first time in our previous study of 16 
pancreatic cancer (17), and the present results further strengthened the credible evidence 17 
for the applicability of this combination of methods to all types of future plasma 18 
biomarker research. Any biomarker candidate identified by proteomic approaches must 19 
be validated using a different method in a statistically sufficient number of cases and 20 
controls before it can be considered for clinical application. We employed another 21 
innovative technology, a reverse-phase protein microarray, for independent validation of 22 
our finding that adipophilin discriminates colorectal cancer (Fig. 2). Our high-density 23 
protein microarray enabled the high-throughput quantification of one protein in 24 
hundreds of clinical samples in one experiment (18), while keeping the required volume 25 
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of each sample to a minimum (nanoliter level). Although the availability of clinical 1 
samples is often limited, it is often necessary to waste hundreds of microlitters of 2 
samples for preliminary experiments involving techniques such as conventional 3 
enzyme-linked immunosorbent assay (ELISA). Because of their minimal sample 4 
requirements, plasma microarrays are considered to be ideal alternatives to ELISAs for 5 
biomarker validation. However, the absolute concentration and optimal cut-off value of 6 
adipophilin were not determined in the present study. It may be necessary to establish an 7 
ELISA prior to the clinical application of the present results. 8 
Although the expression of adipophilin is known to be induced in various types 9 
of pathological and physiological conditions such as lactating mammary epithelial cells, 10 
few studies have assessed the significance of its expression in cancer cells (27, 28). We 11 
found that adipophilin is expressed in well- or moderately-differentiated 12 
adenocarcinomas, but not in the adjacent normal colonic mucosa or 13 
poorly-differentiated adenocarcinoma (Fig. 4). The immunohistochemical data suggest 14 
that the expression of adipophilin is induced during the process of early colorectal 15 
carcinogenesis, but lost during the process of cancer promotion. Consistent with our 16 
findings, Yao et al. also reported that adipophilin expression correlates well with the 17 
differentiation status of clear cell renal carcinoma of the kidney (29). They also reported 18 
that adipophilin expression is a prognostic factor for the cancer-specific survival of 19 
patients with renal clear cell carcinoma (29). The prognostic significance of adipophilin 20 
expression in colorectal cancer, however, remains to be determined. 21 
The expression of adipophilin is known to be regulated by hypoxia inducible 22 
factor (HIF) and the peroxisome proliferator-activated receptor (PPAR) family of 23 
proteins. Both HIF and PPAR were reported to be closely involved in carcinogenesis, 24 
especially in colorectal cancer (30, 31). Moreover, PPARγ may be a molecular target of 25 
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anticancer therapy (32). Since the exact nature of the interactions between these proteins 1 
(adipophilin, HIF, and PPAR) has not been extensively investigated, further studies are 2 
needed to elucidate the biological and clinicopathological significance of adipophilin 3 
expression in colorectal cancer. The present findings may provide novel insights into the 4 
molecular mechanism of colorectal cancer development and progression and into the 5 
development of new anticancer therapeutics. 6 
There are some limitations to our study. First, we have no data regarding the 7 
body-mass index of cases included in the present study. The relationship between 8 
obesity and an increased risk of colon cancer is now generally accepted (33-35), and 9 
alteration of adipocytokine levels can reportedly affect intestinal carcinogenesis (36). 10 
Although adipophilin was originally identified as a marker of adipocyte development 11 
(27, 37), its relevance to body shape and cachexia remain to be elucidated. Adipophilin 12 
is a 50 kDa protein belonging to the PAT family (perilipin, adipophilin, TIP47, S3-12, 13 
and OXPAT), which comprises proteins involved in the coating of lipid droplets (27, 38, 14 
39). Secondly, we have no data of FOB test results for the cases used in this study, and 15 
thus it was not possible to demonstrate the superiority of adipophilin to FOB. However, 16 
a recent large-scale study demonstrated that 11% of patients with negative FOB results 17 
had cancers or adenomas that required treatment (40). Since the adipophilin level was 18 
significantly elevated even in patients with localized early colorectal cancer (Table 2), 19 
adipophilin may supplement or surpass the diagnostic power of FOB. Finally, there was 20 
a difference in the age distribution between cancer and control in all cohorts. However, 21 
age did not correlate with plasma adipophilin level in the cancer and control group 22 
(Pearson’s r = 0.03 and r = 0.09, respectively). We therefore estimate the influence of 23 
difference in age to be negligible. 24 
In conclusion, we identified plasma adipophilin as a new tumor marker for 25 
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colorectal cancer using LMW protein profiling. The increase of plasma adipophilin 1 
level in colorectal cancer was validated in two larger cohorts, and the diagnostic power 2 
was revealed to be superior to that of CEA in the detection of early-stage (stages I and 3 
II) colorectal cancer. To our knowledge, this is the first study demonstrating the 4 
expression of adipophilin in colorectal cancer. While bearing the above limitations in 5 
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FIGURE LEGENDS 1 
Figure 1. 2 
(A) Two-dimensional display of all (>53,000) MS peaks detected. The 103 MS peaks 3 
for which the mean intensity determined in duplicate analyses distinguished between 4 
colorectal cancer and healthy control patients (with AUC values >0.800) are highlighted 5 
in red. 6 
(B) Adipophilin-derived MS peaks in representative patients from cancer and control 7 
groups. Arrows indicate ID 83, at 749 m/z and a RT of 47.4 minutes. 8 
(C) Adipophilin-derived MS peaks (ID 83) in 43 duplicate LC-MS runs aligned 9 
according to RT (top). Columns represent the mean intensity of duplicate analyses of the 10 
43 individuals in the Training cohort (bottom). 11 
(D) Verification of quantitative MS data and protein identification. The levels of plasma 12 
adipophilin and complement C3b-α (loading control) were determined using 13 
immunoblotting in representative colorectal cancer patients and healthy individuals 14 
selected from the Training cohort. Recombinant adipophilin (0.3 μg) was applied as a 15 
positive control (lane next to the molecular weight standard ladder). 16 
 17 
Figure 2. 18 
Representative reverse-phase protein microarray slide of the V1 cohort stained with 19 
anti-ADFP antibody (left). Magnified images of quadruplicate spots of representative 20 
individuals with high and low levels of adipophilin (right). 21 
 22 
Figure 3. 23 
(A, C) Plasma adipophilin level in healthy controls and patients with colorectal cancer 24 
in the V1 (A) and V2 (C) cohorts. Horizontal lines represent the average adipophilin 25 
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level. 1 
(B) ROC analyses illustrating the discriminatory capability of adipophilin in the V1 2 
(solid line) and V2 (dashed line) cohorts. 3 
(D) ROC analyses illustrating the discriminatory value of CEA and the composite index 4 
of adipophilin and CEA in the V1 and V2 cohorts. 5 
 6 
Figure 4. 7 
Immunohistochemical analysis of adipophilin in colorectal cancer (A-D) and adjacent 8 
normal colonic mucosa (designated by N) (C). 9 
Original magnification; A and D = 100×; B = 400×; C = 40×. 10 
 11 
12 
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Table 1.  Clinicopathologic Characteristics of Cases in the Training and Validation Cohorts
Cancer Healthy P Cancer Healthy P Cancer Healthy P
No. of patients 22 21 101 109 26 87






   Male 14 17 63 70 13 56
   Female 8 4 38 39 13 31
Age,  years <0.001 <0.001 <0.001
   mean (SD) 62 (12) 40 (13) 64 (11) 42 (14) 63 (12) 43 (16)
Tumor location NA NA NA
   Colon 22 ― 88 ― 24 ―
   Rectum 0 ― 13 ― 2 ―
Clinical stage NA NA NA
   I 3 ― 19 ― 12 ―
   II 6 ― 31 ― 5 ―
   III 8 ― 32 ― 8 ―
   IV 5 ― 17 ― 1 ―
   unknown 0 ― 2 ― 0 ―
CA19-9
   median,  U/mL 14.7 5.5 0.010 4 1.6 <0.001 9.4 10.2 0.680
   >37.0 (ULN),  no. of patients 6 2 39 5 2 4
CEA
   median,  ng/mL 3.5 1.7 0.002 11.8 7.6 0.001 2.6 1.7 0.008
   >5.0 (ULN),  no. of patients 9 1 24 5 4 5
Total bilirubin
   median,  mg/dL 0.4 0.5 0.114 0.4 0.5 <0.001 0.4 0.5 <0.001
   >1.2 (ULN),  no. of patients 0 0 1 3 0 4
Adipophilin
   Mass spectrometry peak intensity
†
,  mean (SD) 320 (375) 96 (78) <0.001
§ ― ― ― ―
   Protein intensity
‡
,  mean (SD) ― ― 3.91 (0.06) 3.82 (0.13) <0.001
|| 3.57 (0.14) 3.42 (0.20) <0.001
||
‡Measured using reverse-phase protein microarray (logarithmic variable).  §Calculated using Mann-Whitney U -test.  ||Calculated using Welch's t- test.
Abbreviations: SD, standard deviation; NA, not applicable; ULN, upper limit of normal.
Training Cohort (n = 43) Validation-1 Cohort (n = 210) Validation-2 Cohort (n = 113)
NOTE. Wilcoxon test was applied to assess differences between values.  *Calculated by Fisher's exact test.  †Intensity of the corresponding peak as measured using quantitative mass spectrometry.
Stage I Stage II Stage III Stage IV
No. of cases 19 31 32 17 109
Adipophilin
*
,  mean (SD) 3.90 (0.05) 3.91 (0.07) 3.91 (0.07) 3.93 (0.03) 3.82 (0.13)








CEA,  mean (SD),  ng/mL 2.63 (1.71) 13.7 (36.2) 224 (1068) 200 (579) 2.07 (1.74)
   P † (vs. healthy controls) 0.20 0.09 0.25 0.18 ―
†Welch's t-test (comparison to healthy controls).  
Abbreviation: SD, standard deviation.
Table 2.  Plasma Adipophilin and CEA Levels According to Clinical Stage of Colorectal Cancer (V1 Cohort)
Healthy Controls
Colorectal Cancer Patients
*Measured using a reverse-phase protein microarray (values were transformed into logarithmic variables).
LEGEND FOR SUPPLEMENTARY FIGURE 
Supplementary Figure S1 (online). 
MS/MS spectra and database search result for a single MS peak (ID 83) derived from 
adipophilin. The adipophilin peptide matching the amino acid sequence in the database 
is highlighted in red (bottom). 
 
 
LIST OF TABLES 
Supplementary Table S1 (online). 
Plasma Proteins for which the MS Peak Intensity Differed Significantly between 





MS/MS Fragmentation of EMAENGV
Found in ADFP_HUMAN, Adipophilin (Adipose differentiation-related protein) 
(ADRP) - Homo sapiens (Human)
Match to Query 2: 748.347984 from(749.355260,1+)
Monoisotopic mass of neutral peptide Mr(calc): 748.3061
Ions Score: 44        Expect: 0.21
Matches (Bold Red): 10/26 fragment ions using 25 most intense peaks
# a a* b b* Seq. y y* #
1 102.0550 130.0499 E 7
2 233.0954 261.0904 M 620.2708 603.2443 6
3 304.1326 332.1275 A 489.2304 472.2038 5
4 433.1751 461.1701 E 418.1932 401.1667 4
5 547.2181 530.1915 575.2130 558.1864 N 289.1506 272.1241 3
6 604.2395 587.2130 632.2345 615.2079 G 175.1077 2
7 V 118.0863 1
Supplementary Table S1.  Plasma Proteins for which the MS Peak Intensity Differed Significantly Between Healthy Controls and Patients with Colorectal Cancer 
Gene locus Protein identification Mascot score AUC Matched
peptide
HBD HUMAN Hemoglobin subunit delta (Hemoglobin delta chain) (Delta-globin) - Homo sapiens (Human) 90.18 0.86 1
HBB HUMAN Hemoglobin subunit beta (Hemoglobin beta chain) (Beta-globin) - Homo sapiens (Human) 74.50 0.82 5
RETBP_HUMAN Plasma retinol-binding protein precursor (PRBP) (RBP) [Contains: Plasma retinol-binding protein (1-
182); Plasma retinol-binding protein (1-181); Plasma retinol-binding protein (1-179); Plasma retinol-
binding protein (1-176)] - Homo sapiens (Human)
66.52 0.82 1
HBA HUMAN Hemoglobin subunit alpha (Hemoglobin alpha chain) (Alpha-globin) - Homo sapiens (Human) 63.75 0.81 2
ADFP HUMAN Adipophilin (Adipose differentiation-related protein) (ADRP) - Homo sapiens (Human) 43.67 0.81 1
PKDRE_HUMAN Polycystic kidney disease and receptor for egg jelly-related protein precursor (PKD and REJ homolog) -
Homo sapiens (Human)
41.62 0.81 1
NOTE.  *Peaks with a Mascot score >40.
